Product Overview
Dragon Pharma Aromasin is exemestane in 25 mg oral tablets, shipped as a 100 tablet pack. Exemestane belongs to the steroidal class of aromatase inhibitors: it acts as a false substrate for the aromatase enzyme and inactivates it permanently, which is why reference material calls it an inactivator rather than a reversible blocker. The pack is produced under GMP conditions with HPLC verification of the active content, so a tablet split down the score line delivers the dose that was planned.
Its role is narrow. Exemestane does not add muscle, does not raise testosterone and is not a cycle on its own; it manages the estradiol that aromatizing compounds generate. Because the enzyme is replaced only when the body synthesizes new aromatase, a single tablet keeps suppression going for several days even though the terminal half-life is about 24 hours. That gap between half-life and real duration is the reason every-other-day dosing is common. Users who want a reversible inhibitor instead compare it with Arimidex, and anyone who needs heavier suppression looks at Femara.
The reader this pack suits is a man running an aromatizing cycle who wants water and gynecomastia risk held down without flattening estrogen completely. Long, steady cycles built on Enantat 250 or on a multi-ester blend are the natural home for it, because aromatization there is predictable and slow enough to answer a slow-acting drug.
Dosage Protocol
The tablet is 25 mg and very few users need the whole of it at the start. Doses below come from the reference data collected for this card and from established practice of pulling the dose by estradiol results.
| Beginner | 12.5 mg every other day, for as long as the aromatizing base runs; a deliberately low entry point chosen by bloodwork |
| Intermediate | 12.5-25 mg every other day; irreversible inhibition means the effect outlives the half-life |
| Advanced | 25 mg per day, only when a confirmed high estradiol reading justifies it |
| Female | Not used in this context; the sources hold no confirmed protocol for female athletes, and the drug is documented as a clinical treatment under medical supervision, not as a sports supplement |
| Administration | Oral, tablets, commonly every other day; the scheme is built from lab results rather than from symptoms |
A tablet can be broken across the score line to reach 12.5 mg. Because the drug works by removing enzyme rather than by blocking a receptor for a few hours, taking 25 mg every other day and 12.5 mg daily are not interchangeable in practice: the first produces a taller peak and a deeper trough, which can show up as joint discomfort on the low days.
On-Cycle Support Protocols
Exemestane is always the supporting compound, never the headline. These three combinations show where it fits in a Dragon Pharma stack.
What to Expect
- Estradiol and bloat. A drop in estrogen-driven water is usually visible within the first one to two weeks at 12.5 mg every other day.
- Duration of effect. Suppression continues for several days after the last tablet, because the enzyme has to be rebuilt from scratch.
- Low estrogen signals. Flushes, night sweats and unusual tiredness mean the dose has gone too far rather than not far enough.
- Joints. Aching knees and shoulders are the most common complaint once estrogen sits below the useful range.
- High doses. Above the therapeutic range the drug starts producing androgen-like effects such as acne and weight gain.
- Measurement. The dose is selected from estradiol numbers, not from how the cycle feels on a given day.
- Limitation. This is a supporting compound: it will not add size, strength or vascularity on its own, and it cannot replace the base.
Side Effects and Management
Almost every complaint on exemestane traces back to driving estrogen lower than the body needs, so the fix is nearly always a lower dose rather than another tablet.
Estrogen Control After the Cycle
Exemestane is not a recovery agent. It does not restart natural production and it does not act as post-cycle therapy, so the exit from the drug is simply the end of the need for estrogen control.
